Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.38 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.36 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2352361 | 0.98 | GABBR2 (0.39) | ACHENAAADGKAHTR2CPRSS1 | |
| SCHEMBL1037005 | 0.86 | MGLL (0.41) | ACHEDGKAGABBR2GABBR1 | |
| SCHEMBL2355094 | 0.83 | ACHE (0.40) | ACHENAAADGKAHTR2CPRSS1 | |
| SCHEMBL1037481 | 0.81 | DGKA (0.50) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL13498178 | 0.81 | FAAH (0.53) | P2RY10GPR34 | |
| SCHEMBL13109397 | 0.80 | TSHR (0.53) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL258496 | 0.77 | TSHR (0.49) | DGKAHTR2CPRSS1PRSS2PRSS3 | |
| SCHEMBL2526191 | 0.77 | NAAA (0.55) | ACHENAAADGKAHTR2CPRSS1 | |
| SCHEMBL2525587 | 0.77 | NAAA (0.55) | ACHENAAADGKAHTR2CPRSS1 | |
| SCHEMBL7267842 | 0.77 | NAAA (0.55) | ACHENAAADGKAHTR2CPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1832596-B1 | Compounds of mono-carboxyl functionalised dialkylphosphine acids and other components | CLARIANT FINANCE BVI LTD (VG) | 2011-01-26 | — | — | EP | claimed |
| US-20070210288-A1 | Mixtures composed of monocarboxy-functionalized dialkylphosphinic esters and of further components | CLARIANT INTERNATIONAL LTD | 2007-09-13 | — | — | US | claimed |
| EP-1832596-A1 | Compounds of mono-carboxyl functionalised dialkylphosphine acids and other components | CLARIANT INTERNATIONAL LTD. (CH) | 2007-09-12 | — | — | EP | claimed |
| EP-1832596-B1 | Compounds of mono-carboxyl functionalised dialkylphosphine acids and other components | CLARIANT FINANCE BVI LTD (VG) | 2011-01-26 | — | — | EP | disclosed |
| US-7485745-B2 | Mixtures composed of monocarboxy-functionalized dialkylphosphinic esters and of further components | CLARIANT INTERNATIONAL LTD. (CH) | 2009-02-03 | — | — | US | disclosed |
| US-20070210288-A1 | Mixtures composed of monocarboxy-functionalized dialkylphosphinic esters and of further components | CLARIANT INTERNATIONAL LTD | 2007-09-13 | — | — | US | disclosed |
| EP-1832596-A1 | Compounds of mono-carboxyl functionalised dialkylphosphine acids and other components | CLARIANT INTERNATIONAL LTD. (CH) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070210288-A1 | Mixtures composed of monocarboxy-functionalized dialkylphosphinic esters and of further components | ALKBH3, FFAR3, EBP | ACHE 4792/4885NAAA 3904/4885DGKA 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.